{"entity":{"id":"nct04478279","kind":"trial","name":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Temozolomide in melanoma and prostate cancer, run by Sapience Therapeutics, active and no longer recruiting.","summary":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04478279 by Sapience Therapeutics, with 125 participants enrolled, started 2020-07-01 and due to reach its primary completion in 2026-12. Interventions recorded: ST101, Temozolomide, Radiation. Conditions listed: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04478279","url":"https://clinicaltrials.gov/study/NCT04478279"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","prostate","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04478279","phase":"1/2","setting":"A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors","sponsor":"Sapience Therapeutics","enrolled":125,"outcomes":[]},"route":"/trials/nct04478279/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}